- Home
- AVIR vs IMRX Comparison
AVIR vs IMRX Comparison
Compare AVIR & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- IMRX
- Stock Information
- Founded
- AVIR 2012
- IMRX 2008
- Country
- AVIR United States
- IMRX United States
- Employees
- AVIR N/A
- IMRX N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- AVIR Health Care
- IMRX Health Care
- Exchange
- AVIR Nasdaq
- IMRX Nasdaq
- Market Cap
- AVIR 290.4M
- IMRX 232.9M
- IPO Year
- AVIR 2020
- IMRX 2021
- Fundamental
- Price
- AVIR $3.27
- IMRX $6.81
- Analyst Decision
- AVIR Hold
- IMRX Strong Buy
- Analyst Count
- AVIR 1
- IMRX 4
- Target Price
- AVIR $6.00
- IMRX $17.75
- AVG Volume (30 Days)
- AVIR 453.6K
- IMRX 1.5M
- Earning Date
- AVIR 11-07-2025
- IMRX 11-10-2025
- Dividend Yield
- AVIR N/A
- IMRX N/A
- EPS Growth
- AVIR N/A
- IMRX N/A
- EPS
- AVIR N/A
- IMRX N/A
- Revenue
- AVIR N/A
- IMRX N/A
- Revenue This Year
- AVIR N/A
- IMRX N/A
- Revenue Next Year
- AVIR N/A
- IMRX N/A
- P/E Ratio
- AVIR N/A
- IMRX N/A
- Revenue Growth
- AVIR N/A
- IMRX N/A
- 52 Week Low
- AVIR $2.46
- IMRX $1.10
- 52 Week High
- AVIR $4.02
- IMRX $10.08
- Technical
- Relative Strength Index (RSI)
- AVIR 57.88
- IMRX 55.45
- Support Level
- AVIR $3.15
- IMRX $6.10
- Resistance Level
- AVIR $3.34
- IMRX $6.68
- Average True Range (ATR)
- AVIR 0.10
- IMRX 0.45
- MACD
- AVIR 0.02
- IMRX 0.07
- Stochastic Oscillator
- AVIR 79.37
- IMRX 96.21
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.